Affiliations: Department of Chemistry, Payame Noor University, Tehran, Iran
Correspondence:
[*]
Corresponding author: Asghar Amiri, Department of Chemistry, Payame Noor University, P.O. BOX 19395-3697,
Tehran, Iran. Tel.: +98 9133401546; E-mail: [email protected].
Abstract: The aim of this research was to test the chelation potency of deferasirox (DFS or ICL670)) and deferiprone (L1) in mobilization of arsenic in arsenic-exposed rats. Male Wistar rats were exposed to 60 mg/kg body weight sodium arsenite in drinking water for six weeks, followed by treatment with DFS (80 mg/kg body weight, oral, once daily), L1(100 mg/kg body weight, oral, once daily) alone or in combination, for six consecutive days. After chelation therapy, these rats were anesthetized by ether vapor, were immobilized by cervical dislocation and then their heart, liver, kidneys, intestine and blood were sampled for clinical hematological variables and determination of arsenic and iron concentration by Inductively Coupled Plasma/Optical Emission Spectrometry (ICP-OES). Comparison of single and combined therapy showed that the combined chelation therapy (DFS+L1) is more effective in depleting arsenic concentration from soft tissues. No effects of arsenic or any of the two treatments (L1 or DFS) on WBC, RBC and Hb were observed. Interestingly, platelet counts showed a decrease in arsenic exposure. The obtained Results of combined treatment should be confirmed by a different experimental model before extrapolation to other systems.
